In a world where the population is ageing, there is growing interest and demand for research
evaluating strategies that address the ageing process. After 60 years of successful use of …

Metformin is the most widely prescribed oral hypoglycemic medication for type 2 diabetes
worldwide. Metformin also retards aging in model organisms and reduces the incidence of …

The strong evidence of metformin use in subjects affected by type 2 diabetes (T2DM) on
health outcomes, together with data from pre-clinical studies, has led the gerontological …

Even though the inevitable process of aging by itself cannot be considered a disease, it is
directly linked to life span and is the driving force behind all age-related diseases. It is an …

Aging is a major global challenge, and there is growing demand for new strategies to
address the burden of aging. The intensive search for antiaging agents has led to the …

The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow
aging in humans. While the Targeting Aging with Metformin (TAME) proposal and other …

The numerous beneficial health outcomes associated with the use of metformin to treat
patients with type 2 diabetes (T2DM), together with data from pre-clinical studies in animals …

Background Ageing is characterized by a decline in cognitive and bodily functions.
Metformin, the most commonly prescribed antidiabetic agent today, has proved to be able to …

Metformin represents a striking example of a “historical nemesis” of a drug. About 40 years
after its marketing in Europe, once demonstrated its efficacy and safety, metformin was …

Metformin is a safe, effective and useful drug for glucose management in patients with
diabetes. However in recent years, more attention has been paid to the possibility of using …